诺华(NVS)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

NVS 诺华

交易中 04-28 13:03:33 EDT

144.35

+0.16

+0.11%

最高145.65	最低142.65	成交量166.18万
今开143.97	昨收144.19	日振幅2.08%
总市值2,754亿	流通市值2,621亿	总股本19.08亿
成交额2.40亿	换手率0.09%	流通股本18.16亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"NVS","market":"US","secType":"STK","nameCN":"诺华","latestPrice":144.35,"timestamp":1777395811416,"preClose":144.19,"halted":0,"volume":1661770,"delay":0,"changeRate":0.0011096469935501531,"floatShares":1816000000,"shares":1907999999,"eps":7.15,"marketStatus":"交易中","change":0.16,"latestTime":"04-28 13:03:33 EDT","open":143.97,"high":145.645,"low":142.65,"amount":239730762.27100003,"amplitude":0.020771,"askPrice":144.4,"askSize":188,"bidPrice":144.32,"bidSize":20,"shortable":3,"etf":0,"ttmEps":7.15,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1777406400000},"marketStatusCode":2,"adr":1,"adrRate":1,"exchange":"NYSE","adjPreClose":144.19,"dividendRate":0.032325,"preHourTrading":{"tag":"盘前","latestPrice":143.96,"preClose":144.19,"latestTime":"09:29 EDT","volume":48207,"amount":6858704.434769999,"timestamp":1777382999095,"change":-0.23,"changeRate":-0.001595,"amplitude":0.034815},"postHourTrading":{"tag":"盘后","latestPrice":143.9502,"preClose":144.19,"latestTime":"19:55 EDT","volume":10288,"amount":1483549.8422,"timestamp":1777334120221,"change":-0.2398,"changeRate":-0.001663,"amplitude":0.011295},"volumeRatio":1.957516,"impliedVol":0.2628,"impliedVolPercentile":0.7331},"requestUrl":"/m/hq/s/NVS","defaultTab":"news","newsList":[{"id":"1145136092","title":"诺华Q1销售净额131.1亿美元，不及市场预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1145136092","media":"老虎资讯综合","labels":[],"top":1,"itemType":null,"share":"https://www.laohu8.com/m/news/1145136092?lang=zh_cn&edition=full","pubTime":"2026-04-28 13:50","pubTimestamp":1777355455,"startTime":"0","endTime":"0","summary":"4月28日，$诺华(NVS)$夜盘跌超3%！第一季度销售净额131.1亿美元，市场预估133.6亿美元；第一季度核心净利润37.9亿美元，市场预估39.9亿美元；第一季度核心运营利润49.0亿美元，市场预估51.8亿美元；第一季度核心每股收益1.99美元，市场预估2.10美元。","market":"us","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":"诺华Q1销售净额131.1亿美元，不及市场预期","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0009355771.USD","LU0208291251.USD","BK4532","IE00BJT1NW94.SGD","BK4585","BK4578","IE00BFTCPJ56.SGD","LU0070302665.USD","IE0002141913.USD","BK4007","IE00B4R5TH58.HKD","NVS","LU0211331839.USD","IE00B2B36J28.USD","LU0320765489.SGD","BK4588","IE00BJJMRZ35.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1115331145","title":"由于仿制药冲击严重，诺华一季度利润未达预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1115331145","media":"老虎资讯综合","labels":["corporation"],"top":1,"itemType":null,"share":"https://www.laohu8.com/m/news/1115331145?lang=zh_cn&edition=full","pubTime":"2026-04-28 13:18","pubTimestamp":1777353502,"startTime":"0","endTime":"0","summary":"瑞士制药商 $诺华(NVS)$ 诺华（Novartis）周二公布，其第一季度核心营业利润低于市场预期，原因是其畅销心脏药物Entresto面临美国仿制药竞争，对销售造成压力。经特殊项目调整后的季度集团营业利润为49亿美元，低于Visible Alpha引用的分析师平均预期约51亿美元。","market":"us","thumbnail":"https://community-static.tradeup.com/news/374dbbb7be17d6f7bf0b1b2658569853","type":0,"news_type":0,"thumbnails":["https://community-static.tradeup.com/news/374dbbb7be17d6f7bf0b1b2658569853"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"94b5a51f428f47d6930afae9c4511333","theme_name":"热榜No.1 · 2026 Q1财报：LendingClub、纽柯钢铁、新美亚电子、Bed Bath & Beyond业绩齐超预期","theme_type":2,"isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"诺华第一季度利润受美国仿制药冲击而下滑","news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVS"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2630532966","title":"诺华一季度销售净额131.13亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2630532966","media":"第一财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630532966?lang=zh_cn&edition=full","pubTime":"2026-04-28 13:08","pubTimestamp":1777352939,"startTime":"0","endTime":"0","summary":"【诺华一季度销售净额131.13亿美元】诺华发布财报，2026年第一季度销售净额131.13亿美元，营业利润42.35亿美元，核心每股收益1.99美元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604283721992511.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604283721992511.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4585","IE00BJJMRZ35.SGD","BK4532","BK4578","NVS","IE00B4R5TH58.HKD","BK4007","IE00BJT1NW94.SGD","BK4588","LU0320765489.SGD","IE00BFTCPJ56.SGD","LU0070302665.USD","IE0009355771.USD","LU0208291251.USD","IE0002141913.USD","LU0211331839.USD","IE00B2B36J28.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629152808","title":"诺华(NVS)抗疟婴儿药获世卫预认证 以非营利方式供应疫区","url":"https://stock-news.laohu8.com/highlight/detail?id=2629152808","media":"金吾财讯","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629152808?lang=zh_cn&edition=full","pubTime":"2026-04-24 16:12","pubTimestamp":1777018331,"startTime":"0","endTime":"0","summary":"世卫组织相关负责人表示，目前尚无专门针对该体重区间婴幼儿单纯性疟疾的治疗药物，该复方制剂填补了这一空白。诺华在声明中称，将在疟疾流行地区以非营利方式提供该治疗药物，助力提升疫区婴幼儿抗疟治疗可及性。","market":"fut","thumbnail":"https://static.szfiu.com/news/20250107/ZDBhOTg3YTMxNzM2MjM3OTI3ODI2.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/ZDBhOTg3YTMxNzM2MjM3OTI3ODI2.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"299641","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0002141913.USD","BK4007","IE00BJJMRZ35.SGD","IE00BJT1NW94.SGD","LU0320765489.SGD","BK4532","IE00B4R5TH58.HKD","IE00B2B36J28.USD","LU0208291251.USD","LU0070302665.USD","NVS","BK4578","BK4585","BK4588","IE0009355771.USD","LU0211331839.USD","IE00BFTCPJ56.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627447062","title":"Anthropic任命诺华CEO瓦斯·纳拉西姆汉加入董事会","url":"https://stock-news.laohu8.com/highlight/detail?id=2627447062","media":"环球市场播报","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627447062?lang=zh_cn&edition=full","pubTime":"2026-04-14 23:06","pubTimestamp":1776179160,"startTime":"0","endTime":"0","summary":"据报道，人工智能初创公司Anthropic已任命诺华首席执行官瓦斯·纳拉西姆汉 为其董事会成员，这是该公司数月内第二次增补董事会成员。　　此次任命正值Anthropic积极推进IPO计划并进一步拓展医疗保健领域业务之际。　　Anthropic联合创始人丹妮拉·阿莫代伊在一份声明中表示，纳拉西姆汉曾负责监督超过35种创新药物的开发与审批工作，积累了“在监管最为严格的行业之一”的丰富经验。　　此次董事会人事变动是Anthropic加速进军医疗健康领域的最新举措。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-04-14/doc-inhunttt8941455.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4588","IE0002141913.USD","IE00B2B36J28.USD","BK4585","IE00BJJMRZ35.SGD","LU0208291251.USD","LU0320765489.SGD","IE00BFTCPJ56.SGD","IE00BJT1NW94.SGD","BK4532","NVS","LU0211331839.USD","BK4578","LU0070302665.USD","IE0009355771.USD","IE00B4R5TH58.HKD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626185568","title":"诺华(NVS)宣布扩大全球医疗公益 偏远地区推心脑血管与癌症救治","url":"https://stock-news.laohu8.com/highlight/detail?id=2626185568","media":"金吾财讯","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2626185568?lang=zh_cn&edition=full","pubTime":"2026-04-09 18:21","pubTimestamp":1775730088,"startTime":"0","endTime":"0","summary":"金吾财讯 | 诺华制药(NVS)周四宣布，将扩大全球公益项目，面向偏远地区开展心脏病与癌症患者的筛查和治疗。项目覆盖国家将由目前 11 个，增至 2030 年超 30 个，同时纳入美国五座城市。在多国慢性病公共卫生投入放缓的背景下，诺华表示将重点覆盖医疗体系中被忽视的群体。项目将联合当地社区组织、卫生部门及企业，提升预防与早诊服务可及性，优化诊疗转诊与后续康复流程，推动基层慢病规范管理。","market":"nz","thumbnail":"https://static.szfiu.com/news/20210810/NTA4OTM0NjA2MTc=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/NTA4OTM0NjA2MTc=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"298971","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0002141913.USD","BK4578","LU0070302665.USD","IE00BJJMRZ35.SGD","BK4588","LU0208291251.USD","BK4585","IE0009355771.USD","LU0211331839.USD","159891","IE00BJT1NW94.SGD","IE00BFTCPJ56.SGD","LU0320765489.SGD","BK4007","NVS","IE00B4R5TH58.HKD","IE00B2B36J28.USD","BK4532"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622487680","title":"诺华拟斥高达20亿美元收购生技公司Excellergy","url":"https://stock-news.laohu8.com/highlight/detail?id=2622487680","media":"金吾财讯","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622487680?lang=zh_cn&edition=full","pubTime":"2026-03-27 23:43","pubTimestamp":1774626210,"startTime":"0","endTime":"0","summary":"金吾财讯 | 诺华将斥高达20亿美元收购生技公司Excellergy，交易预计将于今年下半年完成，但需满足包括获得监管部门批准在内的各项条件。收购协议将包括首期付款及里程碑付款。透过今次交易，诺华将收购Excellergy的候选药物Exl-111，这是一种抗IgE抗体，目前处于早期测试阶段，可补充公司现有的过敏产品组合。","market":"sh","thumbnail":"https://static.szfiu.com/news/20250107/ZDBhOTg3YTMxNzM2MjM3OTI3ODI2.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/ZDBhOTg3YTMxNzM2MjM3OTI3ODI2.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"298472","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4532","IE00B4R5TH58.HKD","IE0009355771.USD","IE00BFTCPJ56.SGD","BK4007","IE00BJJMRZ35.SGD","IE00BJT1NW94.SGD","NVS","LU0070302665.USD","LU0208291251.USD","BK4578","IE00B2B36J28.USD","LU0211331839.USD","LU0320765489.SGD","IE0002141913.USD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622845105","title":"诺华制药(NVS.US)20亿美元收购Excellergy 加码食物过敏与免疫疾病赛道","url":"https://stock-news.laohu8.com/highlight/detail?id=2622845105","media":"智通财经","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622845105?lang=zh_cn&edition=full","pubTime":"2026-03-27 15:36","pubTimestamp":1774597007,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，诺华制药已同意以高达20亿美元的价格收购生物技术公司Excellergy Inc.，此项交易将强化其在食物过敏及其他免疫疾病治疗领域的产品组合。此次收购的核心资产是Excellergy公司研发的创新候选药物Exl-111。从行业影响来看，Excellergy的加入将使诺华制药在过敏性疾病领域拥有更具差异化的产品组合。此外，诺华制药还于去年10月宣布了其最大规模投资之一——以120亿美元收购Avidity Biosciences公司，随后又陆续达成多项针对过敏性疾病及乳腺癌药物的交易合作。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1420347.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0320765489.SGD","IE00BJT1NW94.SGD","IE00BFTCPJ56.SGD","IE00B4R5TH58.HKD","IE00BJJMRZ35.SGD","IE0002141913.USD","BK1191","LU0070302665.USD","BK4588","BK1574","IE00B2B36J28.USD","BK4578","BK4532","NVS","LU0211331839.USD","LU0208291251.USD","01477","BK4007","IE0009355771.USD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622302684","title":"阿里健康与诺华达成数字化慢病合作 共建慢性荨麻疹院外管理新模式","url":"https://stock-news.laohu8.com/highlight/detail?id=2622302684","media":"人民财讯","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622302684?lang=zh_cn&edition=full","pubTime":"2026-03-25 16:37","pubTimestamp":1774427820,"startTime":"0","endTime":"0","summary":"【阿里健康与诺华达成数字化慢病合作 共建慢性荨麻疹院外管理新模式】记者3月25日获悉，阿里健康与诺华制药宣布在慢性自发性荨麻疹（CSU）领域达成数字化慢病合作。双方将围绕诺华旗下全球首个口服荨麻疹靶向药瑞米布替尼片（商品名：瑞普多），依托阿里健康的数字化平台能力，提供从疾病科普、用药指导到全周期健康管理的整合式服务。阿里健康依托其长期深耕的“全周期慢病管理体系”，为患者打造一个“院外第二诊室”。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603253684062712.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1591","BK1247","IE00BJJMRZ35.SGD","BK1502","LU0211331839.USD","BK1515","NVS","IE00B2B36J28.USD","BK1615","IE0002141913.USD","IE00BFTCPJ56.SGD","LU0208291251.USD","LU0320765489.SGD","BK4585","LU0070302665.USD","BK1142","IE00BJT1NW94.SGD","BK1610","BK4532","BK4007","BK1571","IE00B4R5TH58.HKD","BK4578","BK1189","00241","BK1501","BK1617","BK1584","BK4588","IE0009355771.USD","BK1589"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621063596","title":"诺华国际业务部总裁：中国是引入创新和谋求合作的绝佳之地","url":"https://stock-news.laohu8.com/highlight/detail?id=2621063596","media":"澎湃新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621063596?lang=zh_cn&edition=full","pubTime":"2026-03-24 17:39","pubTimestamp":1774345140,"startTime":"0","endTime":"0","summary":"自2015年以来，在政策、人才、资本等多重力量的推动下，中国医药创新取得长足发展，创新活力和成果引发全球瞩目。2026年是“十五五”开局之年，“十五五”规划纲要提出，加快生物医药等战略性新兴产业发展。2026年的政府工作报告也提出“推动创新药高质量发展”，并首次将生物医药列入“新兴支柱产业”。宏观政策信号持续释放，产业定位进一步提升，中国医药创新有望迎来新的发展窗口。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202603243682667347.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603243682667347.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4585","IE00BJJMRZ35.SGD","LU0211331839.USD","BK4578","IE00B4R5TH58.HKD","BK4532","LU0320765489.SGD","LU0208291251.USD","NVS","IE00BJT1NW94.SGD","IE00B2B36J28.USD","IE00BFTCPJ56.SGD","IE0002141913.USD","BK4588","BK4007","IE0009355771.USD","LU0070302665.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621236627","title":"诺华万思瀚：人工智能等新兴技术正进一步放大医疗创新的影响","url":"https://stock-news.laohu8.com/highlight/detail?id=2621236627","media":"睿见Economy","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621236627?lang=zh_cn&edition=full","pubTime":"2026-03-23 10:07","pubTimestamp":1774231620,"startTime":"0","endTime":"0","summary":"　　中国发展高层论坛2026年年会于3月22日至23日在北京召开，本届论坛主题为“‘十五五’的中国：高质量发展与共创新机遇”。诺华公司首席执行官万思瀚在“健康中国2030”与大健康产业发展专题研讨会上重点探讨了两个核心议题：医疗健康领域创新投资的重要性，以及如何确保创新在未来持续在中国发展以应对挑战。　　万思瀚强调，人工智能等新兴技术正进一步放大医疗创新的影响。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/meeting/2026-03-23/doc-inhrxvtt5381419.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["IE00B2B36J28.USD","159891","NVS","LU0070302665.USD","BK4588","BK4007","LU0208291251.USD","IE0009355771.USD","IE00BJT1NW94.SGD","IE00BFTCPJ56.SGD","IE00B4R5TH58.HKD","BK4532","BK4585","IE0002141913.USD","BK4578","161631","LU0211331839.USD","IE00BJJMRZ35.SGD","LU0320765489.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621719156","title":"诺华宣布加大在华投资 预计将投入金额超过33亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2621719156","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621719156?lang=zh_cn&edition=full","pubTime":"2026-03-22 16:13","pubTimestamp":1774167236,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK4588","IE0002141913.USD","NVS","LU0320765489.SGD","IE00B4R5TH58.HKD","IE00BFTCPJ56.SGD","LU0070302665.USD","IE00B2B36J28.USD","BK4578","IE00BJJMRZ35.SGD","BK4007","IE00BJT1NW94.SGD","LU0208291251.USD","IE0009355771.USD","BK4532","BK4585","LU0211331839.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620780632","title":"诺华(NVS.US)拟斥资30亿美元收购Synnovation Therapeutics乳腺癌药物资产","url":"https://stock-news.laohu8.com/highlight/detail?id=2620780632","media":"智通财经","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620780632?lang=zh_cn&edition=full","pubTime":"2026-03-20 18:58","pubTimestamp":1774004312,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，诺华集团同意以最高30亿美元的价格收购Synnovation Therapeutics旗下一款实验性乳腺癌药物，以强化其肿瘤学产品管线。根据市场汇编的分析师预期，诺华目前用于治疗此类乳腺癌的药物Piqray，今年销售额预计将下滑9%，至约3.48亿美元。诺华称，该药物旨在精准靶向肿瘤细胞，同时减少对正常细胞的影响，这种策略有望\"为患者带来更好的耐受性和更持久的获益\"。截至周四，诺华股价年内累计上涨6.6%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1416688.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE00B4R5TH58.HKD","IE0002141913.USD","IE00BJT1NW94.SGD","LU0070302665.USD","IE00BFTCPJ56.SGD","LU0211331839.USD","BK4578","BK4585","IE00BJJMRZ35.SGD","LU0208291251.USD","BK4588","IE00B2B36J28.USD","BK4007","BK4539","BK4532","BK4139","IE0009355771.USD","LU0320765489.SGD","NVS","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620786602","title":"诺华以30亿美元收购实验性乳腺癌药物","url":"https://stock-news.laohu8.com/highlight/detail?id=2620786602","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620786602?lang=zh_cn&edition=full","pubTime":"2026-03-20 16:17","pubTimestamp":1773994655,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["IE00BFTCPJ56.SGD","IE00BJJMRZ35.SGD","IE00B4R5TH58.HKD","BK4007","BK4578","NVS","IE00BJT1NW94.SGD","LU0320765489.SGD","BK4588","IE0002141913.USD","BK4532","IE00B2B36J28.USD","LU0070302665.USD","LU0211331839.USD","LU0208291251.USD","BK4585","IE0009355771.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620276284","title":"诺华司库奇尤单抗获得美国FDA批准用于治疗12岁以上儿童中重度化脓性汗腺炎患者","url":"https://stock-news.laohu8.com/highlight/detail?id=2620276284","media":"人民财讯","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620276284?lang=zh_cn&edition=full","pubTime":"2026-03-18 14:06","pubTimestamp":1773813987,"startTime":"0","endTime":"0","summary":"人民财讯3月18日电，诺华宣布，司库奇尤单抗已获得美国食品药品监督管理局（FDA）批准，用于12岁及以上儿童中重度化脓性汗腺炎（HS）患者的治疗。司库奇尤单抗作为该人群中唯一获批的IL-17A抑制剂，为HS儿童患者提供了差异化的生物制剂治疗选择。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603183675829931.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["IE00B4R5TH58.HKD","BK4532","IE00BFTCPJ56.SGD","IE00BJJMRZ35.SGD","LU0211331839.USD","BK4588","BK4007","LU0208291251.USD","NVS","IE00B2B36J28.USD","LABU","IE0009355771.USD","BK4585","IE0002141913.USD","BK4578","LU0320765489.SGD","LU0070302665.USD","IE00BJT1NW94.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614856698","title":"诺和诺德、诺华、强生、默沙东等“集体豪赌”，口服生物药这么难还要砸？","url":"https://stock-news.laohu8.com/highlight/detail?id=2614856698","media":"MedTrend医趋势","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614856698?lang=zh_cn&edition=full","pubTime":"2026-02-27 18:44","pubTimestamp":1772189087,"startTime":"0","endTime":"0","summary":"2月25日，诺和诺德宣布与麻省理工学院传奇科学家Robert Langer实验室分拆公司Vivtex达成深度合作，交易总额最高达21亿美元，共同开发下一代代谢类药物的口服递送技术。2019年，诺和诺德Rybelsus在美获批上市，成为全球首个口服GLP-1受体激动剂。截至2025年底，其累计销售额已突破百亿美元量级，足以证明口服生物药的巨大潜力。人体本能地阻止大分子进入体内，这是生理保护机制。高盛预测，到2030年口服减重药将占据接近四分之一的市场份额。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260227185632a4370c43&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260227185632a4370c43&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0320765489.SGD","LU0006306889.USD","LU0965509283.SGD","IE00BLSP4452.SGD","LU1244550221.USD","LU2471134879.HKD","SG9999002224.SGD","LU1032955483.USD","LU2750360997.AUD","BK4532","LU0320765646.SGD","LU0265550946.USD","LU0106261372.USD","LU0787776722.HKD","LU0965509101.SGD","LU2361044865.SGD","BK4592","LU2471134952.CNY","LU2461242641.AUD","LU2133065610.SGD","IE00BDGV0183.EUR","SGXZ57979304.SGD","JNJ","SG9999014542.SGD","LU2023250504.SGD","NVO","LU2129689431.USD","BK4533","IE0001KFT4U8.USD","LU1032466523.USD","LU1674673428.USD","BK4550","LU1506573853.SGD","IE00BGHQF631.EUR","LU0795875169.SGD","LU1894683348.USD","LU0070302665.USD","LU1066051225.USD","LU0266013472.USD","IE00B2B36J28.USD","BK4581","LU1983299246.USD","SG9999001176.SGD","LU1935042991.SGD","LU2750360641.GBP","LU2468319806.SGD","LU0792757196.USD","LU2361045086.USD","LU0203347892.USD","LU1066051811.HKD","LU0211331839.USD","LU1430594728.SGD","LU0345770308.USD","LU2129689605.HKD","IE00B1BXHZ80.USD","LU1732799900.SGD","IE00BFTCPJ56.SGD","IE00BJT1NW94.SGD","LU0432979614.USD","SG9999015358.SGD","LU0795875086.SGD","LU0345769128.USD","LU0965508806.USD","LU1059921491.USD","LU0114720955.EUR","IE00BJJMRZ35.SGD","BK4516","IE0034235303.USD","IE00BLSP4239.USD","LU1974910355.USD","IE00B7SZLL34.SGD","LU0203345920.USD","LU0345769631.USD","LU1196500208.SGD","LU1894683264.USD","LU0124676726.USD","LU0130517989.USD","LU1989772840.SGD","LU2129689514.USD","SG9999013999.USD","LU1037948541.HKD","LU0098860793.USD","LU0208291251.USD","IE00BKVL7J92.USD","LU0058720904.USD","IE00BVYPNV92.GBP","LU0122379950.USD","LU0130102774.USD","LU1934455194.USD","BK4588","LU2347655156.SGD","LU1929549753.HKD","LU2324357040.USD","LU1571399168.USD","LU0477156953.USD","LU0234570918.USD","LU1037948897.HKD","LU1066051498.USD","LU2505996681.GBP","LU1718418525.SGD","01276","LU0912757837.SGD","LU2430703251.USD","IE00B3PB1722.GBP","LU0965509010.AUD","LU1989772923.USD","IE00BBT3K403.USD","LU1496350502.SGD","IE00B4R5TH58.HKD","LU1699723380.USD","LU1934455863.HKD","BK4007","LU1244550577.SGD","LU1941712348.USD","NVOX","IE0002141913.USD","IE00B42XCP33.USD","LU0265550359.USD","LU2106854487.HKD","IE00B19Z3581.USD","SG9999014559.SGD","LU0234572021.USD","LU2471134523.USD","BK4504","LU1093756168.USD","LU0648001328.SGD","LU1674673691.USD","LU1069347547.HKD","LU1074936037.SGD","LU1934455277.USD","LU1941712264.USD","LU1061106388.HKD","LU1221951129.SGD","LU1989771016.USD","LU2112291526.USD","IE00BVYPNW00.USD","LU1267930813.SGD","LU2361044949.HKD","MRK","LU1116320737.USD","LU2430703178.SGD","LU1201861249.SGD","LU1291159041.SGD","LU2360032135.SGD","LU0683600562.USD","LU1116320901.HKD","LU0882574055.USD","LU0154236417.USD","BK4599","NVS","LU1023059063.AUD","LU0289739699.SGD","IE00BN8TJ469.HKD","LU0980610538.SGD","SG9999001176.USD","LU1035773651.USD","LU0345770993.USD","SG9999014575.USD","LU1093756325.SGD","LU1261432733.SGD","LU1057294990.SGD","LU2602419157.SGD","LU2505996509.AUD","LU0238689110.USD","SG9999001440.SGD","LU1066053197.SGD","LU2023250843.SGD","IE0002270589.USD","LU2125154778.USD","LU0070217475.USD","LU1244550494.USD","BK4578","IE00B3T34201.USD","LU1162221912.USD","LU0466842654.USD","LU1914381329.SGD","LU1917777945.USD","IE00BFXG1179.USD","LU1221951046.USD","IE00BZ1G4Q59.USD","LU2089984988.USD","LU2430703095.HKD","LU0861579265.USD","SG9999002232.USD","BK4568","BK4585","BK4559","LU0640476718.USD","LU2471134796.USD","IE00BSNM7G36.USD","LU1778281490.HKD","NVOH","SG9999015341.SGD","LU1585245621.USD","IE00B19Z3B42.SGD","LU1280957306.USD","LU2592432038.USD","LU0985320562.USD","IE0009355771.USD","IE000M9KFDE8.USD","LU2125154935.USD","LU0889566641.SGD","LU0689626769.HKD","SG9999014567.USD","LU1732800096.USD","BK4534"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2614308246","title":"诺华制药拟在德州新建放射性配体疗法生产基地","url":"https://stock-news.laohu8.com/highlight/detail?id=2614308246","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614308246?lang=zh_cn&edition=full","pubTime":"2026-02-25 21:02","pubTimestamp":1772024578,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["IE0002141913.USD","IE00B4R5TH58.HKD","LU0070302665.USD","LU0211331839.USD","BK4578","BK4532","LU0208291251.USD","NVS","LU0320765489.SGD","IE00BFTCPJ56.SGD","IE00B2B36J28.USD","01477","BK1574","BK4588","IE00BJJMRZ35.SGD","IE00BJT1NW94.SGD","BK4585","BK1191","BK4007","IE0009355771.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614428702","title":"海量财经｜诺华CEO2.3亿年薪背后：一场业绩、股价与长期价值的精密对赌","url":"https://stock-news.laohu8.com/highlight/detail?id=2614428702","media":"海报新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614428702?lang=zh_cn&edition=full","pubTime":"2026-02-25 17:22","pubTimestamp":1772011353,"startTime":"0","endTime":"0","summary":"全球医药行业的聚光灯，在2026年初悄然转向瑞士巴塞尔。跨国制药巨头诺华发布2025财年业绩，全球净销售额545.32亿美元，同比增长8%；营业收入176.44亿美元，同比大增25%，核心营业利润率突破40%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202602253654131088.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["IE00BJJMRZ35.SGD","BK4007","IE00BJT1NW94.SGD","IE00B2B36J28.USD","NVS","BK4588","IE0009355771.USD","BK4578","LU0208291251.USD","LU0211331839.USD","IE0002141913.USD","IE00BFTCPJ56.SGD","IE00B4R5TH58.HKD","LU0320765489.SGD","BK4585","LU0070302665.USD","BK4532"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614554709","title":"【市场】17个国谈药拟进院，独家品种霸屏","url":"https://stock-news.laohu8.com/highlight/detail?id=2614554709","media":"米内网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614554709?lang=zh_cn&edition=full","pubTime":"2026-02-25 16:07","pubTimestamp":1772006826,"startTime":"0","endTime":"0","summary":"精彩内容近日，成都市第六人民医院发布招标公示，将组织拟引入药品生产企业遴选工作。17个新药在列，均为国谈药，涵盖化学药及生物药，既有环泊酚注射液等超10亿大品种，亦有芦比前列酮软胶囊、替戈拉生片等2025年前三季度销售额增速达三位数的高增长品种。17个新药均为国谈药，目前均已纳入国家医保乙类目录，主要集中在消化系统及代谢、神经系统、心脑血管系统等治疗领域，可见以慢病药、常见病药为主。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202602251615059541ed56&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202602251615059541ed56&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","LU1093756168.USD","BK4599","NVOH","NVS","BK4588","600276","BK4585","NVOX","01276","IE00BZ1G4Q59.USD","LU0154236417.USD","002653","LU1093756325.SGD","IE00BKVL7J92.USD","002793","NVO","BK4532"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2612293950","title":"诺华同意以144.6亿卢比向投资财团出售印度子公司70.68%的股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2612293950","media":"环球市场播报","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2612293950?lang=zh_cn&edition=full","pubTime":"2026-02-20 23:37","pubTimestamp":1771601820,"startTime":"0","endTime":"0","summary":"诺华  已同意将其在诺华印度有限公司持有的70.68%股份，以144.6亿卢比的价格，出售给由WaveRise Investments、ChrysCapital Fund X和Two Infinity Partners组成的投资财团，从而有效结束了其在2024年2月宣布的战略评估。此次评估聚焦于这家在印度上市的子公司，该公司负责销售处方药、仿制药和非处方药。市场反应迅速：在孟买交易中，诺华印度股价一度上涨19.3%，至996.50卢比，交易价格高于公开要约收购价。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-02-20/doc-inhnnsse2737863.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["IE00BFTCPJ56.SGD","BK4585","IE00BJT1NW94.SGD","IE00BJJMRZ35.SGD","LU0208291251.USD","NVS","LU0211331839.USD","BK4578","BK4007","IE0002141913.USD","BK4532","IE00B2B36J28.USD","LU0070302665.USD","IE00B4R5TH58.HKD","BK4588","LU0320765489.SGD","MNDmain","IE0009355771.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.novartis.com","stockEarnings":[{"period":"1week","weight":-0.045},{"period":"1month","weight":-0.0269},{"period":"3month","weight":-0.0528},{"period":"6month","weight":0.1838},{"period":"1year","weight":0.2858},{"period":"ytd","weight":0.0458}],"compareEarnings":[{"period":"1week","weight":0.0091},{"period":"1month","weight":0.1279},{"period":"3month","weight":0.0283},{"period":"6month","weight":0.0404},{"period":"1year","weight":0.2988},{"period":"ytd","weight":0.0488}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Novartis AG于1996年2月29日根据瑞士法律注册成立，为股份公司。公司是一家创新医药公司，从事研究、开发、制造、分销、营销和销售范围广泛的医药产品。它专注于核心治疗领域，包括心血管、肾脏和代谢疾病、免疫学、神经科学和肿瘤学。","yearOnYearQuotes":[{"month":1,"riseRate":0.423077,"avgChangeRate":-0.007884},{"month":2,"riseRate":0.461538,"avgChangeRate":-0.004502},{"month":3,"riseRate":0.5,"avgChangeRate":-0.002232},{"month":4,"riseRate":0.692308,"avgChangeRate":0.015842},{"month":5,"riseRate":0.68,"avgChangeRate":0.009252},{"month":6,"riseRate":0.576923,"avgChangeRate":0.011998},{"month":7,"riseRate":0.692308,"avgChangeRate":0.011407},{"month":8,"riseRate":0.423077,"avgChangeRate":0.001152},{"month":9,"riseRate":0.692308,"avgChangeRate":0.009673},{"month":10,"riseRate":0.423077,"avgChangeRate":-0.013123},{"month":11,"riseRate":0.615385,"avgChangeRate":0.016411},{"month":12,"riseRate":0.692308,"avgChangeRate":0.020635}],"exchange":"NYSE","name":"诺华","nameEN":"Novartis AG"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"诺华(NVS)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供诺华(NVS)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"诺华,NVS,诺华股票,诺华股票老虎,诺华股票老虎国际,诺华行情,诺华股票行情,诺华股价,诺华股市,诺华股票价格,诺华股票交易,诺华股票购买,诺华股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"诺华(NVS)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供诺华(NVS)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}